555win cung cấp cho bạn một cách thuận tiện, an toàn và đáng tin cậy [kết quả xổ số miền nam thứ bảy hàng tuần]
Aug 9, 2025 · Background The first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) has evolved from chemotherapy alone to chemoimmunotherapy. However, the …
Jan 13, 2021 · Context Key Objective Based on results of the pivotal IMpower133 study, atezolizumab (anti–programmed death-ligand 1 [anti–PD-L1]) in combination with carboplatin …
Atezolizumab has demonstrated enhanced safety and efficacy in individuals with SCLC. Its mechanism involves the inhibition of PD-L1 protein signalling, leading to improved tumour …
Oct 3, 2018 · In a clinical trial of patients with advanced small cell lung cancer (SCLC), atezolizumab (Tecentriq), combined with standard chemotherapy, modestly increased …
Sep 25, 2018 · The addition of atezolizumab to chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer resulted in significantly longer overall survival and …
Abstract Objectives: IMbrella A is a Phase III extension study that allowed rollover from Roche/Genentech-sponsored atezolizumab trials, including IMpower133, a Phase I/III trial of …
ALEXANDRIA, Va. — Results from a global phase 3 clinical trial found that maintenance therapy with a combination of lurbinectedin and atezolizumab helped some patients with extensive …
On March 18, 2019, the Food and Drug Administration approved atezolizumab (TECENTRIQ, Genentech Inc.) in combination with carboplatin and etoposide, for the first-line treatment of …
Jun 14, 2025 · Despite improved efficacy with first-line immune checkpoint inhibitors plus platinum-based chemotherapy for extensive-stage small-cell lung cancer (ES-SCLC), survival …
Abstract Purpose The addition of immune checkpoint inhibitors to chemotherapy has improved survival outcomes in patients with extensive-stage small cell lung cancer (ES-SCLC). …
Bài viết được đề xuất: